Rosiglitazone or pioglitazone in type 2 diabetes?

Corinne S de Vries; D L Russell-Jones

doi:10.1136/bmj.b3076

Rosiglitazone or pioglitazone in type 2 diabetes?

Corinne S de Vries, D L Russell-Jones

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

6 Citations (SciVal)

Original language	English
Article number	b3076
Journal	British Medical Journal
Volume	339
DOIs	https://doi.org/10.1136/bmj.b3076
Publication status	Published - 2009

Keywords

risk
cardiovascular death
congestive-heart-failure
mortality
thiazolidinedione use

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmj.b3076

Cite this

@article{d4a2843d240b40fbbf36e1ec8704d1b8,

title = "Rosiglitazone or pioglitazone in type 2 diabetes?",

keywords = "risk, cardiovascular death, congestive-heart-failure, mortality, thiazolidinedione use",

author = "{de Vries}, {Corinne S} and Russell-Jones, {D L}",

year = "2009",

doi = "10.1136/bmj.b3076",

language = "English",

volume = "339",

journal = "British Medical Journal",